NCT00760864 - Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis | Biotech Hunter

Enrollment

432

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

September 30, 2005

Study Completion Date

September 30, 2005

Conditions

Arthritis, Rheumatoid

Interventions

DRUG

TAK-715 and methotrexate

TAK-715 25 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.

DRUG

TAK-715 and methotrexate

TAK-715 50 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.

DRUG

TAK-715 and methotrexate

TAK-715 100 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.

DRUG

Methotrexate

TAK-715 placebo-matching, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks